We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 67.01 | 67.11 | 67.40 | 12 | 09:23:06 |
From May 2022 to May 2024
By Colin Kellaher
Gilead Sciences on Tuesday said it is bolstering its early pipeline in oncology and inflammation through the acquisition of privately held biotech company XinThera.
Foster City, Calif., biopharmaceutical company Gilead didn't disclose terms of the acquisition, but said it expected the deal to reduce earnings this year by 12 cents to 15 cents a share.
Gilead said it is gaining the rights to a portfolio of small molecule inhibitors targeting the PARP1 enzyme for oncology and the MK2 enzyme for inflammatory diseases that could enter clinical trials later this year.
Gilead said both programs have the potential to address multiple indications, offering development opportunities alone and in combination with its current portfolio.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 09, 2023 08:59 ET (12:59 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
